Antiangiogenic Agents for Nonmalignant Brain Tumors

Abstract

Objective To assess the treatment response and side effects for the use of antiangiogenic agents such as vascular endothelial growth factor (VEGF) inhibitors for patients with vestibular schwannomas and meningiomas.

Design and Methods Retrospective review of eight male and two female patients (ages 14 to 70, mean 36 years), treated with bevacizumab (9) or pazopanib (1). Six patients had neurofibromatosis type 2 (NF2) with bilateral vestibular schwannomas and meningiomas, and the four others had aggressive recurrent meningiomas.

Results During treatment (range 4 to 21 months, mean 9.1) with antiangiogenic agents, two patients with an atypical meningioma and radiation necrosis had dramatic partial response, the six NF2 patients had stable or slightly improved disease, and two meningioma patients had disease progression. Hearing was stable in three of the NF2 patients and was improved in three NF2 patients (one of whom received a cochlear implant). Minor toxicities included epistaxis, nausea, diarrhea, weight loss, and abdominal pain. No grade 3 or 4 toxicities were observed.

Conclusion Antiangiogenic agents appear to be safe for the treatment of patients with nonmalignant brain tumors, and in select cases may be efficacious.

Keywords

brain tumor - meningioma - vestibular schwannoma - vascular endothelial growth factor - neurofibromatosis - bevacizumab - pazopanib

• References

• 1 Pechlivanis I, Wawrzyniak S, Engelhardt M, Schmieder K. Evidence level in the treatment of meningioma with focus on the comparison between surgery versus radiotherapy. A review. J Neurosurg Sci 2011; 55 (4) 319-328
• 2 Louis DN, Ramesh V, Gusella JF. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain Pathol 1995; 5 (2) 163-172
• 3 Stangerup SE, Tos M, Caye-Thomasen P, Tos T, Klokker M, Thomsen J. Increasing annual incidence of vestibular schwannoma and age at diagnosis. J Laryngol Otol 2004; 118 (8) 622-627
• 4 Stangerup SE, Tos M, Thomsen J, Caye-Thomasen P. True incidence of vestibular schwannoma?. Neurosurgery 2010; 67 (5) 1335-1340 , discussion 1340
• 5 Plotkin SR, Stemmer-Rachamimov AO, Barker II FG , et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009; 361 (4) 358-367
• 6 Mautner VF, Nguyen R, Knecht R, Bokemeyer C. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 2010; 21 (11) 2294-2295
• 7 Mautner VF, Nguyen R, Kutta H , et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-oncol 2010; 12 (1) 14-18
• 8 Cayé-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup SE. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 2003; 113 (12) 2129-2134
• 9 Cayé-Thomasen P, Werther K, Nalla A , et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 2005; 26 (1) 98-101
• 10 Preusser M, Hassler M, Birner P , et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol 2012; 31 (5) 352-360
• 11 Preusser M, Spiegl-Kreinecker S, Lötsch D , et al. Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer 2012; 118 (20) 5038-5049
• 12 Nayak L, Iwamoto FM, Rudnick JD , et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 2012; 109 (1) 187-193
• 13 Lou E, Sumrall AL, Turner S , et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 2012; 109 (1) 63-70
• 14 Wang P, Ni RY, Chen MN, Mou KJ, Mao Q, Liu YH. Expression of aquaporin-4 in human supratentorial meningiomas with peritumoral brain edema and correlation of VEGF with edema formation. Genet Mol Res 2011; 10 (3) 2165-2171
• 15 Matuschek C, Bölke E, Nawatny J , et al. Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlenther Onkol 2011; 187 (2) 135-139
• 16 Genentech I. Highlights of prescribing information: Avastin. 2011 http://www.gene.com/download/pdf/avastin_prescribing.pdf
• 17 Hwang EI, Jakacki RI, Fisher MJ , et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 2012;
• 18 Packer RJ, Jakacki R, Horn M , et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009; 52 (7) 791-795